vs

Side-by-side financial comparison of AVIENT CORP (AVNT) and Cooper Companies (The) (COO). Click either name above to swap in a different company.

Cooper Companies (The) is the larger business by last-quarter revenue ($1.1B vs $760.6M, roughly 1.4× AVIENT CORP). Cooper Companies (The) runs the higher net margin — 7.9% vs 2.2%, a 5.7% gap on every dollar of revenue. On growth, Cooper Companies (The) posted the faster year-over-year revenue change (4.6% vs 1.9%). Cooper Companies (The) produced more free cash flow last quarter ($149.9M vs $125.4M). Over the past eight quarters, Cooper Companies (The)'s revenue compounded faster (6.9% CAGR vs -4.2%).

Avient Corporation is a global materials solutions company headquartered in Avon Lake, Ohio, United States, employing approximately 9,000 people worldwide. Its products include colorants, advanced composites, functional additives and engineered materials.

The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California. The company consists of two business units, CooperVision (CVI) which manufactures contact lenses, and CooperSurgical (CSI), which manufactures medical devices and fertility and genomic products for the women's healthcare market.

AVNT vs COO — Head-to-Head

Bigger by revenue
COO
COO
1.4× larger
COO
$1.1B
$760.6M
AVNT
Growing faster (revenue YoY)
COO
COO
+2.7% gap
COO
4.6%
1.9%
AVNT
Higher net margin
COO
COO
5.7% more per $
COO
7.9%
2.2%
AVNT
More free cash flow
COO
COO
$24.5M more FCF
COO
$149.9M
$125.4M
AVNT
Faster 2-yr revenue CAGR
COO
COO
Annualised
COO
6.9%
-4.2%
AVNT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AVNT
AVNT
COO
COO
Revenue
$760.6M
$1.1B
Net Profit
$16.9M
$84.6M
Gross Margin
30.2%
61.1%
Operating Margin
5.2%
13.2%
Net Margin
2.2%
7.9%
Revenue YoY
1.9%
4.6%
Net Profit YoY
-65.0%
-28.0%
EPS (diluted)
$0.18
$0.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVNT
AVNT
COO
COO
Q4 25
$760.6M
$1.1B
Q3 25
$806.5M
$1.1B
Q2 25
$866.5M
$1.0B
Q1 25
$826.6M
$964.7M
Q4 24
$746.5M
$1.0B
Q3 24
$815.2M
$1.0B
Q2 24
$849.7M
$942.6M
Q1 24
$829.0M
$931.6M
Net Profit
AVNT
AVNT
COO
COO
Q4 25
$16.9M
$84.6M
Q3 25
$32.6M
$98.3M
Q2 25
$52.6M
$87.7M
Q1 25
$-20.2M
$104.3M
Q4 24
$48.3M
$117.5M
Q3 24
$38.2M
$104.7M
Q2 24
$33.6M
$88.9M
Q1 24
$49.4M
$81.2M
Gross Margin
AVNT
AVNT
COO
COO
Q4 25
30.2%
61.1%
Q3 25
30.4%
65.3%
Q2 25
32.1%
67.8%
Q1 25
31.8%
68.4%
Q4 24
34.8%
66.5%
Q3 24
32.1%
66.1%
Q2 24
30.3%
67.0%
Q1 24
33.6%
67.0%
Operating Margin
AVNT
AVNT
COO
COO
Q4 25
5.2%
13.2%
Q3 25
8.3%
16.6%
Q2 25
11.1%
18.4%
Q1 25
0.1%
18.9%
Q4 24
11.5%
19.5%
Q3 24
9.5%
19.2%
Q2 24
8.5%
17.2%
Q1 24
11.3%
16.4%
Net Margin
AVNT
AVNT
COO
COO
Q4 25
2.2%
7.9%
Q3 25
4.0%
9.3%
Q2 25
6.1%
8.7%
Q1 25
-2.4%
10.8%
Q4 24
6.5%
11.5%
Q3 24
4.7%
10.4%
Q2 24
4.0%
9.4%
Q1 24
6.0%
8.7%
EPS (diluted)
AVNT
AVNT
COO
COO
Q4 25
$0.18
$0.42
Q3 25
$0.36
$0.49
Q2 25
$0.57
$0.44
Q1 25
$-0.22
$0.52
Q4 24
$0.53
$0.59
Q3 24
$0.41
$0.52
Q2 24
$0.36
$0.44
Q1 24
$0.54
$0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVNT
AVNT
COO
COO
Cash + ST InvestmentsLiquidity on hand
$110.6M
Total DebtLower is stronger
$1.9B
$2.5B
Stockholders' EquityBook value
$2.4B
$8.2B
Total Assets
$6.0B
$12.4B
Debt / EquityLower = less leverage
0.81×
0.30×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVNT
AVNT
COO
COO
Q4 25
$110.6M
Q3 25
$124.9M
Q2 25
$116.2M
Q1 25
$100.9M
Q4 24
$107.6M
Q3 24
$109.7M
Q2 24
$112.4M
Q1 24
$135.2M
Total Debt
AVNT
AVNT
COO
COO
Q4 25
$1.9B
$2.5B
Q3 25
$2.0B
$2.4B
Q2 25
$2.0B
$2.5B
Q1 25
$2.1B
$2.5B
Q4 24
$2.1B
$2.6B
Q3 24
$2.1B
$2.6B
Q2 24
$2.1B
$2.7B
Q1 24
$2.1B
$2.7B
Stockholders' Equity
AVNT
AVNT
COO
COO
Q4 25
$2.4B
$8.2B
Q3 25
$2.4B
$8.4B
Q2 25
$2.4B
$8.3B
Q1 25
$2.3B
$8.1B
Q4 24
$2.3B
$8.1B
Q3 24
$2.4B
$7.9B
Q2 24
$2.3B
$7.8B
Q1 24
$2.3B
$7.7B
Total Assets
AVNT
AVNT
COO
COO
Q4 25
$6.0B
$12.4B
Q3 25
$6.1B
$12.4B
Q2 25
$6.1B
$12.4B
Q1 25
$5.8B
$12.2B
Q4 24
$5.8B
$12.3B
Q3 24
$6.0B
$12.1B
Q2 24
$5.9B
$12.0B
Q1 24
$5.9B
$12.0B
Debt / Equity
AVNT
AVNT
COO
COO
Q4 25
0.81×
0.30×
Q3 25
0.83×
0.29×
Q2 25
0.86×
0.30×
Q1 25
0.90×
0.31×
Q4 24
0.89×
0.32×
Q3 24
0.88×
0.33×
Q2 24
0.90×
0.34×
Q1 24
0.90×
0.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVNT
AVNT
COO
COO
Operating Cash FlowLast quarter
$167.8M
$247.9M
Free Cash FlowOCF − Capex
$125.4M
$149.9M
FCF MarginFCF / Revenue
16.5%
14.1%
Capex IntensityCapex / Revenue
5.6%
9.2%
Cash ConversionOCF / Net Profit
9.93×
2.93×
TTM Free Cash FlowTrailing 4 quarters
$195.0M
$433.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVNT
AVNT
COO
COO
Q4 25
$167.8M
$247.9M
Q3 25
$72.1M
$261.4M
Q2 25
$112.8M
$96.2M
Q1 25
$-51.1M
$190.6M
Q4 24
$122.6M
$268.1M
Q3 24
$71.1M
$207.5M
Q2 24
$105.9M
$111.0M
Q1 24
$-42.8M
$122.7M
Free Cash Flow
AVNT
AVNT
COO
COO
Q4 25
$125.4M
$149.9M
Q3 25
$47.4M
$164.5M
Q2 25
$85.8M
$18.1M
Q1 25
$-63.6M
$101.2M
Q4 24
$81.5M
$128.1M
Q3 24
$46.1M
$118.5M
Q2 24
$74.5M
$36.9M
Q1 24
$-67.2M
$4.6M
FCF Margin
AVNT
AVNT
COO
COO
Q4 25
16.5%
14.1%
Q3 25
5.9%
15.5%
Q2 25
9.9%
1.8%
Q1 25
-7.7%
10.5%
Q4 24
10.9%
12.6%
Q3 24
5.7%
11.8%
Q2 24
8.8%
3.9%
Q1 24
-8.1%
0.5%
Capex Intensity
AVNT
AVNT
COO
COO
Q4 25
5.6%
9.2%
Q3 25
3.1%
9.1%
Q2 25
3.1%
7.8%
Q1 25
1.5%
9.3%
Q4 24
5.5%
13.7%
Q3 24
3.1%
8.9%
Q2 24
3.7%
7.9%
Q1 24
2.9%
12.7%
Cash Conversion
AVNT
AVNT
COO
COO
Q4 25
9.93×
2.93×
Q3 25
2.21×
2.66×
Q2 25
2.14×
1.10×
Q1 25
1.83×
Q4 24
2.54×
2.28×
Q3 24
1.86×
1.98×
Q2 24
3.15×
1.25×
Q1 24
-0.87×
1.51×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AVNT
AVNT

Color Additives And Inks$466.0M61%
Specialty Engineered Materials$295.5M39%

COO
COO

Sphere Other$365.0M34%
Toric And Multifocal$344.7M32%
Office And Surgical$214.5M20%
Fertility$140.9M13%

Related Comparisons